Spinal muscular atrophy (SMA) is one of the most common genetic causes of infant death. Since 2017, a number of approved treatments for SMA have been in use and the SMA phenotype is evolving with these disease-modifying therapies.
In this educational webinar led by Khalida Liaquat, MS, CGC, clinical genomic specialist at Blueprint Genetics, the diagnosis and treatment of SMA will be reviewed.
- Review the clinical and molecular diagnosis of SMA
- Identify molecular diagnostic challenges and solutions
- Examine the current and emerging therapies for SMA
Khalida Liaquat, MS, CGC, earned her bachelor’s degree in Biology from Carleton University in Ottawa, Canada and her master’s degree in Human Genetics from Sarah Lawrence College in Bronxville, New York. She is board certified by the American Board of Genetic Counseling since 2009 and is a licensed genetic counselor in the state of Massachusetts. Khalida served as a clinical prenatal and pediatric genetic counselor at Kings County Hospital Center and Woodhull Medical Center in Brooklyn, NY. Currently she is a Clinical Genomic Specialist at Blueprint Genetics. She is also an active member of the National Society of Genetic Counselors, and a member of the CureSMA medical advisory committee.
More details here